A Multicenter, Open-label Study of SI-6603 in Patients with Lumbar Disc Herniation (Phase III)
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 22 Jun 2017
At a glance
- Drugs Condoliase (Primary)
- Indications Intervertebral disc degeneration
- Focus Adverse reactions; Registrational
- Sponsors Seikagaku Corporation
- 21 Jun 2017 This trial has been completed in Germany (end date: 17 Mar 2017).
- 15 Jun 2017 This trial has been completed in Spain (end date: 17 Mar 2017).
- 11 Sep 2016 Planned primary completion date changed from 1 Aug 2017 to 1 Mar 2017.